Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06696768 · ClinicalTrials.gov registry record · Phase 1

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

A Phase 1 study of Stage IV Colorectal Cancer AJCC v8 and Stage III Colorectal Cancer AJCC v8, sponsored by National Cancer Institute (NCI).

Recruiting
Registry status
Phase 1
Development phase
24
Enrollment target
13
Study locations

NCT06696768: Recruiting Phase 1 study of Stage IV Colorectal Cancer AJCC v8 and Stage III Colorectal Cancer AJCC v8, sponsored by National Cancer Institute (NCI).

NCT06696768 is a Phase 1 study of Stage IV Colorectal Cancer AJCC v8 and Stage III Colorectal Cancer AJCC v8 that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 24 participants, below the 107-participant average among 22 other Stage IV Colorectal Cancer AJCC v8 trials with a reported enrollment target (78% lower). The trial reports 13 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06696768, a Phase 1 study of Stage IV Colorectal Cancer AJCC v8 and Stage III Colorectal Cancer AJCC v8, is actively recruiting participants, sponsored by National Cancer Institute (NCI).

RECRUITING
Registry status
Phase 1
Development phase
24 participants
Enrollment target
13
Study locations

Study Summary

This phase I trial studies the side effects and best dose of CA-4948 when given together with fluorouracil, leucovorin, oxaliplatin (FOLFOX) plus bevacizumab in treating patients with colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). CA-4948 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The chemotherapy drugs used in FOLFOX, fluorouracil and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Leucovorin is used with fluorouracil to treat colorectal cancer. Bevacizumab is in a class of medications called anti-angiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to the tumor. This may slow the growth and spread of the tumor. Giving CA-4948 with FOLFOX plus bevacizumab may be safe, tolerable and/or effective in treating patients with metastatic colorectal cancer.

Primary Outcome

DLT will be based on the first 2 cycles (28 days) of emavusertib.

Conditions Studied

Stage IV Colorectal Cancer AJCC v8 Stage III Colorectal Cancer AJCC v8 Metastatic Colorectal Adenocarcinoma Unresectable Colorectal Adenocarcinoma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Biopsy Procedure
  • BIOLOGICAL Bevacizumab
  • BIOLOGICAL Emavusertib

Study Locations (13)

Missouri

  • Siteman Cancer Center at Saint Peters Hospital - City of Saint Peters
  • Siteman Cancer Center at West County Hospital - Creve Coeur
  • Washington University School of Medicine - St Louis
  • Siteman Cancer Center-South County - St Louis
  • Siteman Cancer Center at Christian Hospital - St Louis

Kansas

  • University of Kansas Clinical Research Center - Fairway
  • University of Kansas Cancer Center - Kansas City
  • University of Kansas Hospital-Indian Creek Campus - Overland Park
  • University of Kansas Hospital-Westwood Cancer Center - Westwood

Florida

  • UF Health Cancer Institute - Gainesville - Gainesville

Illinois

  • Memorial Hospital East - Shiloh

Oklahoma

  • University of Oklahoma Health Sciences Center - Oklahoma City

Tennessee

  • Vanderbilt University/Ingram Cancer Center - Nashville

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2025-06-23
Est. Completion 2026-12-31
Phase Phase 1
National Cancer Institute (NCI)

3,257 total trials

What NCT06696768 shows while recruiting

NCT06696768 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 107-participant average among 22 other Stage IV Colorectal Cancer AJCC v8 trials with a reported enrollment target (78% lower).

The record links to 4 conditions, with Stage IV Colorectal Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06696768 lists 13 locations in 6 states (Missouri, Kansas, Florida).

Frequently Asked Questions

What is clinical trial NCT06696768 about?

NCT06696768 is a clinical study titled "Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer". This phase I trial studies the side effects and best dose of CA-4948 when given together with fluorouracil, leucovorin, oxaliplatin (FOLFOX) plus bevacizumab in treating patients with colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic...

What is the current status of trial NCT06696768?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-06-23. Estimated completion is 2026-12-31.

What conditions does trial NCT06696768 study?

This clinical trial studies the following conditions: Stage IV Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Metastatic Colorectal Adenocarcinoma, Unresectable Colorectal Adenocarcinoma.

What interventions are being tested in trial NCT06696768?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy Procedure (PROCEDURE), Bevacizumab (BIOLOGICAL), Emavusertib (BIOLOGICAL).

Who is sponsoring clinical trial NCT06696768?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06696768 being conducted?

This trial has 13 study locations across Florida, Illinois, Kansas, Missouri, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage IV Colorectal Cancer AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06696768's enrollment target sits among peer trials

24 16th of 22 higher than 6 of 22 other Stage IV Colorectal Cancer AJCC v8 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stage IV Colorectal Cancer AJCC v8 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06696768

Source: ClinicalTrials.gov NCT06696768, the US trial registry maintained by the National Library of Medicine. NCT06696768 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.